Preliminary safety and imaging efficacy of the near-infrared fluorescent contrast agent DA364 during fluorescence-guided surgery in dogs with spontaneous superficial tumors.
canine
fluorescence-guided surgery
fluorescent contrast agent
near-infrared fluorescence imaging
spontaneous tumors
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
16 Jun 2020
16 Jun 2020
Historique:
received:
08
01
2020
accepted:
14
05
2020
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
1
7
2020
Statut:
epublish
Résumé
Tumor-targeting contrast agents may facilitate resection of solid neoplasms during fluorescence-guided surgery. Preliminary safety and imaging efficacy of the near-infrared fluorescent probe DA364 were evaluated during surgical resection of spontaneous solid tumors in 24 dogs. Intra-operative imaging was performed
Identifiants
pubmed: 32595830
doi: 10.18632/oncotarget.27633
pii: 27633
pmc: PMC7299531
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2310-2326Informations de copyright
Copyright: © 2020 Favril et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST This manuscript is based on our original research and had neither been published, nor is being considered elsewhere for publication. CB, AC, LM, PO, CA, IT, AM, FT, FB are employees of Bracco Imaging spa. All the other authors declare no commercial or financial conflicts of interest.
Références
Lancet Gastroenterol Hepatol. 2016 Dec;1(4):283-290
pubmed: 28404198
Int J Cancer. 2013 Nov 15;133(10):2362-71
pubmed: 23661241
Eur J Surg Oncol. 2017 Sep;43(9):1656-1667
pubmed: 28579357
Contrast Media Mol Imaging. 2013 Jul-Aug;8(4):350-60
pubmed: 23613438
Front Oncol. 2017 Dec 22;7:314
pubmed: 29312886
PLoS One. 2015 Jun 25;10(6):e0129766
pubmed: 26110901
Ann Surg Oncol. 2018 Oct;25(11):3350-3357
pubmed: 30051369
Mol Imaging Biol. 2016 Feb;18(1):52-61
pubmed: 26084246
Ann Surg. 2015 Jan;261(1):46-55
pubmed: 25599326
J Surg Res. 2012 Sep;177(1):109-15
pubmed: 22516344
J Biomed Opt. 2016 Aug 1;21(8):80901
pubmed: 27533438
Surg Oncol. 2017 Jun;26(2):153-162
pubmed: 28577721
PLoS One. 2014 Jul 29;9(7):e103342
pubmed: 25072388
J Clin Oncol. 2008 Aug 20;26(24):4012-21
pubmed: 18711192
Mol Imaging. 2010 Oct;9(5):237-55
pubmed: 20868625
J Craniomaxillofac Surg. 1991 Oct;19(7):314-8
pubmed: 1752972
PLoS One. 2014 Sep 23;9(9):e106441
pubmed: 25248000
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Mol Imaging Biol. 2019 Feb;21(1):11-18
pubmed: 29845427
Contrast Media Mol Imaging. 2011 Nov-Dec;6(6):449-58
pubmed: 22144022
Oral Oncol. 2005 Nov;41(10):1034-43
pubmed: 16129652
Vet Pathol. 2011 Jan;48(1):19-31
pubmed: 21123864
Cancer Lett. 2013 Jul 1;334(2):188-95
pubmed: 23200675
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
Cancer. 2017 May 15;123(6):1051-1060
pubmed: 28263385
Prostate Cancer. 2011;2011:673021
pubmed: 22110996
Pathophysiology. 2010 Sep;17(4):229-51
pubmed: 20036110
Nat Med. 2011 Sep 18;17(10):1315-9
pubmed: 21926976
Oncotarget. 2017 Nov 30;8(65):109559-109574
pubmed: 29312629
Angew Chem Int Ed Engl. 2011 Jul 4;50(28):6258-63
pubmed: 21656624